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Abstract
Background: The nucleocapsid (NC) protein of HIV-1 is critical for viral replication. Mutational analyses have
demonstrated its involvement in viral assembly, genome packaging, budding, maturation, reverse transcription, and
integration. We previously reported that two conservative NC mutations, His23Cys and His44Cys, cause premature
reverse transcription such that mutant virions contain approximately 1,000-fold more DNA than wild-type virus, and
are replication defective. In addition, both mutants show a specific defect in integration after infection.
Results: In the present study we investigated whether blocking premature reverse transcription would relieve the
infectivity defects, which we successfully performed by transfecting proviral plasmids into cells cultured in the
presence of high levels of reverse transcriptase inhibitors. After subsequent removal of the inhibitors, the resulting
viruses showed no significant difference in single-round infective titer compared to viruses where premature
reverse transcription did occur; there was no rescue of the infectivity defects in the NC mutants upon reverse
transcriptase inhibitor treatment. Surprisingly, time-course endogenous reverse transcription assays demonstrated
that the kinetics for both the NC mutants were essentially identical to wild-type when premature reverse
transcription was blocked. In contrast, after infection of CD4+ HeLa cells, it was observed that while the prevention
of premature reverse transcription in the NC mutants resulted in lower quantities of initial reverse transcripts, the
kinetics of reverse transcription were not restored to that of untreated wild-type HIV-1.
Conclusions: Premature reverse transcription is not the cause of the replication defect but is an independent
side-effect of the NC mutations.
Background
The nucleocapsid (NC) protein of HIV-1 functions
throughout the viral replication cycle, from involvement
in assembly and genomic RNA (gRNA) packaging as
part of the Gag protein (Pr55), to facilitating reverse
transcription as a mature protein (p7). The mechanisms
behind NC’s ability to perform these roles have been
extensively investigated both in vitro and in cell culture
as detailed in the following reviews [1-8].
The role of NC in reverse transcription has been
investigated in considerable detail using a number of
excellent in vitro systems. Because of these thorough
studies, we know that NC can facilitate the tRNA
lys3
annealing to the primer binding site [9-11], dramatically
enhance the efficiency of minus-strand and plus-strand
transfer events [12-19], prevent self-priming (a suicidal
reaction) [13,15,18,20,21], and enhance the processivity
of reverse transcription [22-25]. In addition to reverse
transcription, NC has also been demonstrated to
enhance coupled integration events in vitro [26]. The
fact that NC can assist in all of these processes directly
proceeds from its properties as a nucleic acid chaperone,
which means that NC assists nucleic acids to find the
most thermodynamically stable arrangement resulting in
maximum base pairing [1,2]. Although the general prop-
erties of NC as a nucleic acid chaperone were observed
many years ago in vitro [17,27], the mechanics of how
these properties govern NC’s actions during reverse
transcription is still being elucidated.
We have been interested in examining how NC muta-
tions affect reverse transcription in virions and infected
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NCH44C, have proven to be of great interest in that
although the amino acid alterations are functionally con-
servative with respect to zinc binding, genome packaging,
and virion assembly, the resulting viruses are replication
defective [28-30]. Our initial studies revealed an apparent
defect in viral DNA (vDNA) stability and integration
after infection [31]. After a more detailed kinetic analysis,
we were able to directly demonstrate that integration effi-
ciency was severely impaired for both of these mutants
[32]. Intriguingly, these data also suggested that these NC
mutations appear to cause reverse transcription to initi-
ate much earlier than in wild-type infections. When we
examined the nucleic acids present in NC-mutant virions
prior to infection, we found that they actually contained
a significant amount of vDNA (~1,000-fold more than
WT [33]); virtually every particle had initiated reverse
transcription, and so this process is apparently occurring
prematurely in the viral replication cycle. Similar results
have also been reported by another group with these and
other HIV-1 NC-mutant viruses [34,35]. The exact cause
and the significance of this premature reverse transcrip-
tion are unknown [33,36].
We hypothesized that premature reverse transcription
alone may have been sufficient to block replication of
these viruses. Therefore, we attempted to block premature
reverse transcription in the NC mutants using reverse
transcriptase inhibitors (RTIs) rather than reverse tran-
scriptase (RT) active site mutations. This choice was made
because arresting reverse transcription with inhibitors is
potentially reversible, which would enable us to assess
how well blocking premature reverse transcription affects
viral replication. Additionally, we have observed that active
site point mutations in RT can cause unwanted alterations
in Gag processing (data not shown). A previous study
demonstrated the feasibility of reducing intravirion DNA
by greater than 97% by the addition of 50 μM Nevirapine
(NVP); treatment with 50 μM azidothymadine was only
able to reduce intravirion DNA by 75% [35].
Results
Reverse transcriptase inhibitors prevent infection and can
be effectively removed from virus preparations
Initial experiments were performed to determine the
necessary concentrations of RTIs to use and we found
that a single inhibitor was insufficient to block the levels
of premature reverse transcription that the NC mutations
were causing (data not shown). Virtually every NC-
mutant virus particle contains minus-strand strong-stop
DNA [33], which is extremely difficult to prevent because
it is much more difficult to inhibit the synthesis of short
reverse transcripts (i.e., minus-strand strong-stop DNA)
[37] required for these studies. In contrast, viral replica-
tion can be blocked if the synthesis of the full-length
reverse transcript is stopped at almost any point. We
ultimately found that in order to effectively stop prema-
ture reverse transcription, we needed to add very high
concentrations of two different RTIs to cells, immediately
before transfection of proviral plasmids: 1.0 mM Tenofo-
vir (PMPA) and 50 μM NVP. These two drugs target RT
differently; PMPA is a nucleotide reverse transcriptase
inhibitor (NRTi) that must be incorporated into the nas-
cent DNA while NVP is a non-nucleoside reverse tran-
scriptase inhibitor (NNRTi). The concentrations of each
inhibitor required to completely prevent intravirion DNA
synthesis were more than 1,000-fold higher than their
IC50 levels in cell culture (PMPA: IC50 = 0.1-0.6 μM [38],
NVP: IC50 = 40 nM [39]).
However, our investigations required determining the
properties of virions after premature reverse transcrip-
tion had been blocked, so we developed two different
methods (Figure 1) to remove excess RTIs from virus
preparations once particles were released from the
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Figure 1 Methods to remove RTIs from virus preparations.
Schematic of the two methods used to remove RTIs from virus
preparations. The RTIs were removed so that they did not inhibit
downstream assays to assess viral function when premature reverse
transcription was blocked. In both methods aspiration was used to
remove the supernatant after centrifugation (see the Methods
section for details). The method on the left was used to i) maintain
competent Env proteins on the surface of virions and ii) limit
mechanical stress on virions for subsequent infection analyses. The
method on the right uses DNase I treatment to remove extra-virion
plasmid DNA contamination with subsequent subtilisin digestion to
ensure that the DNase I is completely removed prior to lysis of the
virions, and qPCR analysis of intravirion DNA and endogenous
reverse transcription assays [33].
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could no longer occur. Key to both of these methods is
the collection of the virus particles for complete media
replacement, which reduces the concentration of RTIs
to levels far below what would interfere with reverse
transcription. For subsequent infectivity experiments, we
precipitated virus from culture supernatants with poly-
ethylene glycol (PEG 8000) at 4°C (Figure 1, left). In
contrast, for subsequent assessment of intravirion DNA
levels and endogenous reverse transcription assays, we
used our previously reported protocol for preparing vir-
ions (Figure 1, right; [33]); this rigorous protocol was
f o u n dt ob ee s s e n t i a lf o rr e m o v a lo fe x t r a - v i r i o nc o n -
taminating plasmid DNA to enable accurate determina-
tions of intravirion DNA levels [33]. However, virus
treated by the latter method, which entails subtilisin
digestion to inactivate the DNase I prior to lysing the
virions cannot be used for infectivity assays as all mem-
brane surface proteins, including Env, are digested [40].
Identifying effective methods for removal of RTIs was
initially performed using the VSV-G pseudotyped HIV-1
system that we previously employed [33]. Figure 2 com-
pares single-round TZM-bl infectivity over a serial dilu-
tion series [41] of untreated or RTI-treated VSV-G
C
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Figure 2 RTIs can be effectively removed from virus preparations. Env
(-) VSV-G pseudotyped WT HIV-1 expressed from 293T cells transfected
in the absence (black), or presence of 1.0 mM PMPA (blue) or 50 μM NVP (red), is assayed for limiting-dilution infectivity on TZM-bl cells (panels
A, B and D). The numbers on the X-axes (panels A and B) represent the dilution series, each step being a 3-fold serial dilution starting with 0.1
mL of undiluted infectious supernatant (Dilution 1). For each drug treatment, RTIs were added either immediately before transfection, 24, or 48 h
after transfection as indicated in the legend at the right of panel A. Blue colony forming units (BCFU) were tallied 48 h after the infectivity
experiments were started [41]. Panel A shows the titer of infectious supernatants assayed without PEG precipitation of virus. Panel B shows the
titer of infectious supernatants after PEG precipitation to remove RTIs from the virus stock (see legend from panel A). Panel C shows the yield of
WT virus from each transfection condition (with or without drugs) measured using either qRT-PCR (quantifying gRNA per mL, green) or
exogenous-template RT assays (measuring RT activity in counts per minute of [
32P]-TMP incorporated per mL [CPM per mL], purple). Panel D
shows the titer of the PEG-precipitated WT virus, with the treatments (indicated at the bottom) normalized for the gRNA present in the starting
supernatant (i.e., corrected for dilution). Values are expressed as normalized blue cell forming units (BCFU) and represent the averages from at
least three dilutions (error bars indicate standard deviations).
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Page 3 of 14pseudotyped NCWT virus preparations without (panel A)
or with (panel B) PEG precipitation. It is important to
note that the titer of untreated virus (black line) is the
same, whether the virus was PEG precipitated or not.
However, the titers of viruses treated with either NVP
(red lines) or PMPA (blue lines) are much lower if the
RTIs are not removed (compare panels A and B, red
and blue lines). NVP appears to be more difficult to
remove than PMPA as the peak in PMPA-treated
viruses occurs at a lower dilution than the peak in
NVP-treated virus. This may be due in part to their dif-
ferent modes of action (NRTi vs NNRTi) so that the
dATP present in the infected cells competes with any
remaining unincorporated PMPA in the preparations.
This difference also correlates with the relative effective
concentrations of the two drugs (PMPA is effective in
the μM range while NVP is effective in the nM range).
Interestingly, because PMPA is a chain terminator, it
functions by being incorporated into the nascent vDNA
and thus would not be affected by reducing its concen-
tration in the media. However, it has been shown that
WT RT has the ability to excise nucleosides, including
PMPA in vitro [42,43] and NC can facilitate excision
processes, possibly by stabilizing RT on the nucleic acid
template [42,44]. As will be shown in our assays below,
removal of RTIs is essentially complete.
The fact that the wild-type virus used for the experi-
ments in Figure 2 was VSV-G pseudotyped demon-
strates another effect of the RTI treatment.
Pseudotyping HIV-1 boosts the infectious titer of the
virus produced in part by increasing the total number of
virus particles (Figure 2C). These additional particles are
the product of VSV-G pseudotyped virus infecting the
transfected cells, which we showed previously could be
inhibited by PMPA treatment of the transfected cell cul-
ture [33]. If one compares the yield of virus as a func-
tion of the treatment, one sees that the amount of virus
produced decreases the earlier RTIs are added during
the transfection (Figure 2C). In this chart, virus yields
are determined using either quantitation of genomes by
qRT-PCR or exogenous-template RT activity. Impor-
tantly, these two assays are in excellent agreement,
which shows that the RTIs have been effectively
removed and do not significantly affect the exogenous-
template RT activity. For the majority of subsequent
experiments, gRNA quantitation is used, because it is
the most relevant for determining the efficiency of
reverse transcription; vDNA results are normalized on a
per genome basis throughout. The later RTIs are added
during the transfection, the closer the virus yield
approaches that of the untreated virus so that if RTIs
are added 48 h after the DNA-precipitate is applied to
the 293T cells, there is essentially no effect on virus
yield. We conclude that immediate addition of RTIs to
the transfected cells inhibits VSV-G mediated reinfec-
tion completely because virus yield is no different from
that obtained from transfections without VSV-G (see
below).
While addition of RTIs to transfected cells at earlier
times decreases virus yields, we observed a correspond-
ing increase in the infectivity per virion (Figure 2D).
When RTIs are present from the immediate onset of
the transfection, the infectivity per particle is approxi-
mately 180-fold higher than virus produced without
RTIs (compare black bar with red and blue “immediate”
bars). If RTIs are added 24 h after the transfection, the
infectivity per particle is only 13-fold higher. Finally if
RTIs are added 48 h post transfection, the infectivity per
particle is nearly the same as virus produced without
R T Ie x p o s u r e( F i g u r e2 D ) .T h ed e c r e a s ei nr e l a t i v e
infectivity is likely due to an accumulation of defective
genomes (from the VSV-G pseudotyped wild-type virus
reinfection of the transfected cells mentioned above)
producing non-infectious particles because the reverse
transcription process is inherently error-prone [45]. We
know from previous studies that in this system a repli-
cation cycle occurs every 24 h [46], thus virions have
undergone 2 rounds of replication while being gener-
ated, and genomes are no longer transcribed solely from
transfected plasmids.
RT inhibitors can block premature reverse transcription
For the remainder of this study we chose to use non-
pseudotyped, Env
(+) HIV-1 for several reasons: i) so we
do not need to be concerned with reinfection of trans-
fected cells with the wild-type virus (without RTI treat-
m e n t )a n di i )i tw a sn o t e dp r e v i o u s l yt h a tV S V - G
pseudotyped NC-mutant HIV-1 did not undergo this
amplification since the NC mutants are replication
defective, thus there will not be the tremendous differ-
ence in the numbers of particles produced between
VSV-G pseudotyped NC-mutant and wild-type HIV-1
that was reported previously [33]. This makes compari-
sons of results between untreated and RTI-treated sam-
ples more straightforward.
We transfected 293T cells cultured in the presence of
both PMPA and NVP with NC-mutant and wild-type
proviral plasmids and changed the media after 24 h,
adding fresh RTIs to maintain concentrations as high as
possible. We harvested virus 24 h later, treated with
DNase I and subtilisin to remove extra-virion contami-
nating plasmid DNA (Figure 1, right), and measured
intravirion DNA by quantitative PCR (qPCR) to assess
the levels of minus-strand strong-stop (R-U5), minus-
strand transfer (U3-U5), late minus-strand synthesis
(Gag) and plus-strand transfer (R-5’UTR) targets, and
also gRNA as previously described [33]. Figure 3 shows
that using this method we could quite significantly
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Page 4 of 14(>99.9%) reduce intravirion R-U5 DNA in the NC
mutants to levels below those observed for untreated
wild-type virus (compare red bars in panels B and C,
with black bars in panel A). When one compares the
quantities of intravirion DNA per gRNA, between
untreated and RTI treated samples, there is a 60- to 90-
fold reduction of intravirion DNA in WT virions (panel
A), a 120- to 2,600-fold reduction in NCH23C virions
(panel B), and a 340- to 1,800-fold reduction in NCH44C
virions (panel C), depending on the vDNA target.
After blocking premature reverse transcription, levels
of intravirion DNA per gRNA are very similar between
wild-type and the NC mutant virions (compare red bars
between panels A with B or C [i.e., NCH23C:NCWT =3 -
to 30-fold difference or NCH44C:NCWT =1 -t o4 - f o l d
difference, respectively, depending on the vDNA
species]).
Blocking premature reverse transcription has no effect on
infectious titer of viruses
Figure 4 displays the efficacy of PEG precipitation on
removing RTIs from NCmutant and NCWT virus prepara-
tions. Figure 4A shows the yield of viruses produced in
the absence or presence of RTIs, expressed as
exogenous-template RT activity (in CPM per ml). One
can see that the RT activities are slightly lower in pre-
parations of viruses generated in the presence of RTIs.
The ~2-fold difference here (with non-VSV-G pseudo-
typed viruses) is significantly less than the ~1000-fold
difference between untreated and RTI treated samples
observed with the VSV-G pseudotyped NCWT virus
(Figure 2C), which again has to do with the prevention
of the reinfection of transfected cells using VSV-G pseu-
dotyped virus discussed above. Thus RTI treatment does
not appreciably decrease the amount of virus produced
from cells. Figure 4 also shows the titers of viruses pre-
pared in the presence or the absence of RTIs from two
separate transfection/infection experiments (panels B
and C). These viruses were PEG precipitated (Figure 1,
left) to remove the RTIs. Critically, the titer of wild-type
virus is completely unchanged whether the virus is pre-
pared in the absence (black bars) or presence (red bars)
of RTIs, firmly establishing that we can effectively
remove RTIs from virus preparations. In the case of the
NCH23C and NCH44C viruses, we see that blocking pre-
mature reverse transcription using RTIs had no signifi-
cant effect on infectious titers (Figure 4B and 4C);
importantly, infectivity was not restored to wild-type
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Figure 3 Premature reverse transcription can be blocked. HIV-1 was expressed from 293T cells transfected either in the absence (black bars)
or presence (red bars) of RTIs. Virus was harvested and treated with DNase I and subtilisin, as described in the Methods section (Figure 1, right).
Quantities of intravirion DNA were then measured by qPCR using the reverse transcription intermediate targets [31] indicated at the bottom of
the figure (tRNA, red line; minus-strand DNA, black line; plus-strand DNA, blue line; target sequences indicated by the black dumbbells). The
quantities expressed are the ratio of vDNA to gRNA. Panel A shows wild-type virus, panel B shows NCH23C virus, and panel C shows NCH44C virus.
Values plotted are the means and the errors bars are the standard deviations from two separate experiments.
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Page 5 of 14levels upon RTI treatment with the NC mutants. The
relative difference in the titers of NCWT to that of the
NCmutants is what we normally see when viruses are not
PEG precipitated ([28]; data not shown).
NCmutants display wild-type kinetics during endogenous
reverse transcription
We established that blocking premature reverse tran-
scription did not relieve the infectivity defect; therefore,
we investigated the reverse transcription efficiency of
the NC-mutant and wild-type viruses using an endogen-
ous reverse transcription assay. As before (Figure 3;
[33]) we used our qPCR system to measure the quanti-
ties of each reverse transcription intermediate and then
normalized the vDNA quantities to the amount of
gRNA present at the initiation of the assay to determine
the efficiency of conversion of gRNA to reverse tran-
scripts. We prepared the viruses either in the presence
or the absence of RTIs, and then treated the viruses
with DNase I and subtilisin (Figure 1, right) to remove
not only contaminating extra-virion DNA, but the RTIs
as well. Each virus preparation was then divided into 7
equal aliquots to examine an endogenous reverse tran-
scription time course.
Figure 5 shows the results of these experiments com-
paring the amount of each vDNA species measured as a
function of time. Panels A and B show endogenous
reverse transcription activity from wild-type virus pre-
pared in the absence or the presence of RTIs, respec-
tively. As observed above (Figure 3A) wild-type virus
prepared using the RTI treatment results in a decrease
of the already low levels of intravirion DNA by approxi-
mately 2 logs. This decrease in background actually
enables a more accurate determination of endogenous
reverse transcription activity. When Figures 5A and 5B
are compared, one can see that although the kinetics of
the reactions are similar, the formation of each of the
measured reverse transcription products is much more
efficient. The final quantities of each intermediate are
the same, independent of the presence or absence of
RTIs, while the initial quantities are 2-logs lower in
virus prepared with RTIs. Closer inspection of Figure 5B
shows several important details. Synthesis of R-U5 is
very rapid, and every copy of gRNA gives rise to 1 copy
of R-U5 vDNA. Synthesis of U3-U5 is also fast, although
quantities continue to accumulate until 8 h into the
reaction, when approximately one third of genomes
have progressed to maximal U3-U5 vDNA levels. Gag
targets are noticeably slower in production, with a more
gradual increase to maximum quantities occurring 24 h
into the reaction when approximately one tenth of gen-
omes have progressed to generate maximal Gag vDNA.
Finally, synthesis of R-5’UTR vDNA is the slowest with
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Figure 4 Titer of NC mutant viruses is unchanged if premature
reverse transcription is blocked. Results from HIV-1 produced
either in the absence (black bars) or the presence (red bars) of RTIs
are presented. All viruses produced were PEG precipitated, not just
those treated with RTIs for direct comparison. Panel A shows the
yields of viruses from transfections, with and without RTI treatment
based on average exogenous-template RT activities (in counts per
minute of [
32P]-TMP incorporated per mL [CPM per mL]; error bars
are the standard deviation from duplicate samples). Panels B and C
are from two independent transfection-infection experiments and
each displays the titers of viruses measured using TZM-bl cells,
determined from 3-fold serial dilutions [41]. The titer was corrected
for dilution and input virus as determined by exogenous-template
RT activity and expressed as “Normalized BCFU” from the means of
at least 3 dilutions (error bars represent the standard deviation).
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scribed at 24 h.
Examination of the quantities of vDNA present in the
NCH23C-( F i g u r e5 C )a n dN C H44C-( F i g u r e5 E )m u t a n t
viruses prepared without RTIs reveals a small increase
o v e rt h et i m ec o u r s eo ft h er e a c t i o n( ~ 4 - 1 0 - f o l df o rR -
U5 DNA). As we reported previously [33], these NC
mutants do not have significant endogenous reverse
transcription activity, likely due to the lack of available
gRNA template because of the premature reverse tran-
scription that has taken place during production of the
mutant viruses. However, when we prevent premature
reverse transcription using the RTI treatment, we see
that both NCH23C (Figure 5D) and NCH44C (Figure 5F)
exhibit strong endogenous reverse transcription activity.
For each of the vDNA species examined, the kinetics
and efficiency of formation are virtually identical to
what we observed with wild-type (Figure 5B), with a
~10,000-fold increase in R-U5 vDNA copies over the
time course. Therefore these NC mutants are not defec-
tive in any detectable way for reverse transcription that
takes place within virions. In addition, this assay demon-
strated the likelihood that any PMPA incorporated when
the viruses were generated was effectively removed, as
the efficiencies and kinetics of this reaction are the
same as wild-type. It is possible that some fraction of
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Figure 5 NC mutant viruses display wild-type endogenous reverse transcription kinetics when premature reverse transcription is
blocked. Results of endogenous reverse transcription assays performed with virus generated either in the absence or presence of RTIs as
indicated at the top of the figure. Virus was prepared using sequential DNase I + subtilisin treatment as described (Figure 1, right). At each time
point indicated, a sample of virus was taken and the vDNA was isolated and quantitated. Values were then divided by the number of genomes
present at the start of every endogenous reverse transcription reaction to display the quantity of vDNA as a fraction of available genomes.
Panels A, C, and E show endogenous reverse transcription time courses using viruses (WT, NCH23C,N C H44C, respectively) prepared without RTIs
while panels B, D, and F show time courses with viruses (WT, NCH23C,N C H44C, respectively) prepared in the presence of RTIs. These results are
from a representative experiment. The legend for the vDNA species measured is indicated at the bottom of panel A and the bottom of Figure 3
shows schematics of the pertinent vDNA target sites.
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and was not extended, but this population was not
apparent in this assay.
Blocking premature reverse transcription does not rescue
defective NCmutant reverse transcription kinetics in
infected cells
Although the endogenous reverse transcription activity
of the NC mutants was essentially wild-type when pre-
mature reverse transcription was blocked (Figure 5B, D
and 5F), the single-round TZM-bl infectivity of the NC
mutants was still reduced compared to wild-type, even
after RTI treatment and removal (Figure 4). Because of
this disparity, we decided to examine the reverse tran-
scription activities of these mutants during a time
course of infection. We generated virus in the presence
or absence of RTIs, then PEG-precipitated the viruses
(both RTI-treated and untreated samples; Figure 1, left)
to remove the RTIs, DNase I treated the inocula (see
Methods section), and infected HeLa clone 1022 CD4
(+)
cells with equivalent amounts of virus, based on exogen-
ous-template RT activities. Cells were then harvested
over the time course, total cell DNA was isolated, and
vDNA was measured using qPCR. Previously we had
reported that using this technique, we were able to see
significant differences between wild-type and NC-
mutant vDNA kinetic profiles [32].
The kinetic profiles of vDNA synthesis during a wild-
type infection, with virus prepared without RTIs are
shown in Figure 6A. This chart is similar to what we
had reported previously–a maximum accumulation of
vDNA occurred at 12 h post infection and by 24 h post
i n f e c t i o nt h ea m o u n t so fR - U 5a n dU 3 - U 5a r ea b o u t
twice those of Gag and R-5’UTR. In addition, we do not
see any evidence for reinfection, although it should be
theoretically possible (the cells are CD4+ and the pro-
viral clones are Env
(+)). However, because Env, Nef, and
Vpu can down regulate the CD4 receptor in infected
cells [47,48], the lack of reinfection is not necessarily
surprising. Figures 6C and 6E show the vDNA profiles
after infection with the NCH23C and NCH44C mutants
(without RTI treatment), respectively. As we previously
reported, quantities of vDNA at 4 h were similar to
wild-type, but unlike wild-type, these were the maxi-
mum levels achieved during the entire time course of
infection [32].
When we examined vDNA, after infection with wild-
type HIV-1 prepared in the presence of RTIs (so that
premature reverse transcription was blocked), we saw
that the profiles were very similar to those prepared
without RTIs (compare panels A and B). The peaks in
vDNA syntheses occur at 8 h rather than 12 h, but the
ratios of early and late reverse transcripts are the same
at all the time points 24 h and later. In addition, in this
experiment overall levelso fv D N Aa r ea b o u t5 - f o l d
lower in viruses prepared with RTIs, although this has
no significant effect on single-round infectivity (Figure
4). It is likely that the shift in peak time for vDNA dur-
ing WT infection is due to infecting cells with higher
quantities of virus; when we titrate the amount of virus
used to infect cells we see a similar shift in peak vDNA
times so that the more virus loaded on the cells results
in later vDNA peaks (unpublished observations).
During infections with the NCH23C mutant virus pre-
p a r e dw i t hR T I s( F i g u r e6 D )w es e ead i f f e r e n tp r o f i l e –
although initial levels are still the highest, we see an
accumulation in reverse transcripts causing a second-
ary peak at 12 h, then a steeper decrease over the rest
of the time course compared to virus prepared without
RTIs. In addition, levels of vDNA in the presence of
RTIs are about 5-fold lower after infection compared
with virus prepared without RTIs (compare Figure 6C
and 6D), similar to that observed for the wild-type
virus set (Figure 6A and 6B). We see analogous results
after infection with NCH44C mutant virus (panel F); an
accumulation in reverse transcripts with a peak at 8 h
post infection, but the overall levels are 5-fold lower
than in virus prepared without RTIs (compare panels E
and F). The accumulation of peak reverse transcripts in
NC mutant viruses prepared with RTIs is likely
because these virions do not undergo premature
reverse transcription, thus reverse transcription initi-
ates after infection, as with wild-type virus. The fact
that the overall levels of vDNA are lower in virus pre-
pared with RTIs, yet the TZM-bl infectivity does not
change, indicates that the higher levels of intravirion
DNA present in infections with virus prepared without
RTIs does not contribute to the infectivity of the virus.
The loss of R-U5 products after infection (Figure 6C,
6D and 6F) with the NC mutants is likely due to
degradation of the ends of the viral DNA synthesized
as well as the lack of integration, which have been pre-
viously reported [31,49].
NCWT phenotype is dominant over NCmutants and
infectivity does not correlate with the extent of
premature reverse transcription
We performed the following experiment to test the
relationship between intravirion DNA and infectivity
by testing whether the NCWT or NCmutant phenotypes
were dominant. We cotransfected cells with different
ratios of NCWT and NCmutant proviral plasmids and
examined the virus for infectivity in TZM-bl cells and
also measured quantities of intravirion DNA. Figure
7A shows that as the proportion of NCWT (blue line)
increases relative to NCH23C, the amount of intravirion
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Page 8 of 14DNA (green line) drops much quicker than the
increase in infectivity (red line). However, the increase
in infectivity is directly proportional to the increase in
the amount of NCWT.W es e eas l i g h t l yd i f f e r e n tr e s u l t
with viruses containing different ratios of NCWT to
NCH44C (Figure 7B) because the decrease in intravirion
DNA is more gradual with increasing proportions of
NCWT. However, in agreement with what was observed
with the NCH23C:NCWT mixtures, the increase in infec-
tivity mirrors the relative amount of NCWT present in
the virions. The higher overall levels of infectivity
observed with the NCH44C mutant in this experiment
is due to the inherently higher infectious titer of this
mutant virus compared to NCH23C, (compare red lines
between Figures 7A and 7B) which was reported pre-
viously [28] and is also apparent in Figure 4. These
experiments indicate that the levels of intravirion DNA
are independent of the infectivity of these viruses, and
that the NC mutations are not dominant over WT
HIV-1 with respect to infectivity.
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Figure 6 NC mutant reverse transcription kinetics in cells are altered when premature reverse transcription is blocked. CD4+ HeLa cells
were infected with virus prepared in the absence or presence of RTIs that were subsequently removed using PEG-precipitation (Figure 1, left).
These charts display the profile of reverse transcripts over a 72 h time course of infection. Panels A, C, and E show infections from viruses (WT,
NCH23C, and NCH44C, respectively) not treated with RTIs, and panels B, D, and F show infections from viruses (WT, NCH23C, and NCH44C,
respectively) where premature reverse transcription was blocked via RTI treatment. Prior to the infection, all of the virus samples were normalized
for RT activity so that equal amounts were used to infect each set of cells. These results are from a representative experiment. The vDNA species
measured were normalized for cell equivalents using CCR5 and are indicated at the bottom of panel A. Schematics of the pertinent vDNA target
sites are shown at the bottom of Figure 3.
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When we observed that the NCH23C and NCH44C muta-
tions resulted in premature reverse transcription, we did
not know if this was a direct, indirect, or unrelated
cause of their replication defect [33]. We hypothesized
that the presence of intravirion DNA indicates a defec-
tive virus. This is based, in part, on observations by Mir-
ambeau and coworkers [50-52] and Cruceanu and
coworkers [53] that the mature NC protein (p7) favors
binding to single-stranded nucleic acids and binds less
tightly to double stranded regions. In addition, Zhang
and coworkers reported that when dNTPs were added
to extracellular HIV-1 virions, which stimulated reverse
transcription, electron micrographs revealed indistinct
cores [54]. It seemed reasonable to interpret this core
dissolution as being analogous to core uncoating during
an infection. Because there is very good evidence that
core uncoating is a regulated step during infection
[55-59], any event that alters the timing of this could
potentially disrupt replication [60,61]. Thus, we wanted
to see if the replication defect could be rescued by pre-
venting premature reverse transcription in these NC
mutants. To investigate this we developed an experi-
mental system whereby reverse transcription could be
reversibly inhibited so that we could examine the effects
of blocking the accumulation of high levels of intravir-
ion DNA on infectivity and reverse transcription
processes.
In this study, we showed that completely inhibiting
premature reverse transcription (Figure 3) did not res-
cue the single-round infectivity defects associated with
the NC mutants (Figure 4). In contrast to this, we found
that when premature reverse transcription was blocked,
the endogenous reverse transcription kinetics of these
mutants could be restored to nearly the wild-type level
(Figure 5B, D, and 5F). However, during infection of
HeLa CD4+ cells, we did see that the NCH23C mutant
still showed poor reverse transcription profiles with
apparently unstable reverse transcripts (Figure 6D) after
RTI treatment. The NCH44C mutant showed a profile
similar to NCH23C virus (compare Figure 6D and 6F).
The difference in reverse transcription efficiencies dur-
ing endogenous reverse transcription versus infection is
probably related to the inability of core components to
readily diffuse or “uncoat” from the viral core in the
endogenous reverse transcription system, as they are
maintained within the viral membrane as is discussed
below.
The absolute quantities of vDNAs are lower after
infections with viruses prepared in the presence of
RTIs compared to those prepared without RTIs (Figure
6), however, the infectious titer remains unchanged
(Figure 4). This indicates that the amount of intravir-
ion vDNA is irrelevant with respect to infection read-
out in the TZM-bl assay. Or stated differently, the
altered timing of reverse transcription in the NC
mutants does not significantly change the infectivity of
these viruses using TZM-bl cells as the readout. This
conclusion is supported by our experiments with
NCWT and NCmutant mixtures. In these experiments,
infectious titer is directly related to the amount of
NCWT p r e s e n ti nt h ev i r i o n s ,n o tt ot h ea m o u n to f
intravirion DNA (Figure 7).
The results from our endogenous reverse transcription
time course experiments (Figure 5) are important
because we did not see that these NC mutations caused
any defects in the kinetics or efficiencies of reverse tran-
scription. Several in vitro reverse transcription systems
using purified proteins and short defined templates do
show reverse transcription defects with these NC
mutant proteins [15,62]. The reason for these differ-
ences may be as straightforward as protein concentra-
tions. Endogenous reverse transcription occurs within
the confines of the virus membrane so that even after
24 h the majority of CA, MA, and NC are still pelletable
(data not shown). In addition, if the virus preparations
are diluted out prior to endogenous reverse transcrip-
tion (such as in the time course experiments) the reac-
tions proceed no differently than if the virus is
maintained at a high concentration. Because of this, it is
likely that during endogenous reverse transcription, the
NC protein is maintained at very high concentrations
with respect to the viral gRNA. Based on the volume of
the conical core of HIV-1 as estimated from cryo-elec-
tron tomography [63], and assuming that each virion
contains 2000 NC molecules [64], the effective concen-
tration of NC within the core is ~100 mM.
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Figure 7 NCWT phenotype is dominant over NCmutants with no
correlation between infectivity and premature reverse
transcription. 293T cells were cotransfected with the indicated
ratios of NCWT or NCmutant proviral plasmids. The percentage of
NCWT in each transfection is shown in blue. The resulting viruses
were harvested and infectious titer in TZM-bl cells was determined
(red). The resulting titers were corrected for input virus and are
expressed as a percentage of WT titer. The amount of intravirion
DNA (R-U5) was also quantified in each sample (green), and these
values are expressed as a percentage of intravirion DNA present for
each respective NCmutant virus (so that 100% mutant is defined as
100% intravirion DNA). The values are the average of 2 separate
experiments and the error bars indicate the standard deviations.
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endogenous reverse transcription activity upon RTI treat-
ment with subsequent inhibitor removal (Figure 5B, D, F),
in the context of an infection, the NC mutants still show
defects in reverse transcription compared to wild-type
virus (Figure 6). Thus there is something about reverse
transcription within the intracellular environment that
prevents these NC mutants from productively replicating
in a cell. Previously, we had postulated that premature
reverse transcription may cause altered uncoating or
reverse transcription complex maturation [33], but we
now know that premature reverse transcription is not the
cause of the replication defect. It is important to point out
that the reverse transcripts generated during the infection
time course (Figure 6D and 6F) appear more unstable
with NC-mutant viruses prepared in the presence of RTIs
(premature reverse transcription being blocked), which
would indicate that integration is still defective. Although
we would like to have examined integration directly using
the Alu-LTR qPCR assay as we performed in our previous
study [32], the sensitivity of this assay is not amenable to
the measurement of integration products with non VSV-G
pseudotyped virus infections using HeLa CD4+ cells.
However, it is possible that NC is more directly involved
during the integration event, as was shown in a previous
report using purified integrase and NC in a cell-free, in
vitro assay [26]. In that study, both of these NC mutants
showed a defect in integration compared to wild-type NC.
How much this would carry through to infected cells is
difficult to say considering that additional viral and cellular
protein cofactors are involved [57,59,65].
Conclusions
We have blocked premature reverse transcription in NC
mutant viruses using high levels of RTIs. Upon removal
of the inhibitors, the single-round TZM-bl infectivity of
these mutants remained the same, independent of
whether premature reverse transcription occurred or was
blocked. Endogenous reverse transcription assays demon-
strated that reverse transcription for these NC mutants
displayed wild-type kinetics and efficiencies. However,
reverse transcription in the context of an infection was
still defective compared to wild-type virus. Cotransfec-
tion experiments with various ratios of NCWT and NCmu-
tant plasmids also failed to show any correlation between
intravirion DNA and infectivity. Therefore premature
reverse transcription is not the clear-cut cause of the
replication defect for these viruses, but is likely a symp-
tom of some other defect in the assembly process.
Methods
Chemicals and plasmids
Nevirapine was obtained through the AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID,
NIH, and handled according to the supplied data sheet
(https://www.aidsreagent.org/pdfs/ds4666_004.pdf).
Tenofovir (PMPA) was kindly provided by Gilead
S c i e n c e s ,I n c .( F o s t e rC i t y ,C A ) .C o n s t r u c t i o no ft h e
NCH23C and NCH44C mutants in pNL4-3 (GenBank
accession numbers AF324493 and M19921) [66] were
previously described [28]. A frameshift mutation was
introduced into the env of the indicated proviral clones
to prevent expression of Env [67]. The plasmid pHCMV-
g, which expresses VSV-G [68], was a kind gift from Jane
Burns (University of California, San Diego).
Cell culture and transfections
293T cells [69,70], HeLa CD4+ Clone 1022 (obtained
through the AIDS Research and Reference Reagent Pro-
gram, Division of AIDS, NIAID, NIH: from Dr. Bruce
Chesebro https://www.aidsreagent.org/pdfs/ds1109_009.
pdf) [71-73], and TZM-bl cells (obtained through the
NIH AIDS Research and Reference Reagent Program,
Division of AIDS, NIAID, NIH: from Dr. John
C. Kappes, Dr. Xiaoyun Wu and Tranzyme Inc. https://
www.aidsreagent.org/pdfs/ds8129_010.pdf) [74-78] were
maintained as described [28,41]. Transfections were per-
formed using CaPO4 co-precipitation as previously
described [32,33] with Env
(+) v i r u s( F i g u r e s3 ,4 ,5 ,6 ,7 )
or Env
(-)/VSV-G pseudotyped virus (Figure 2). For RTI
treatments we used 50 μM NVP and 1 mM PMPA.
Both drugs were added just prior to the addition of
DNA precipitates to cells. Cell culture fluids were chan-
ged 24 h post transfection and replaced with fresh
media containing the same levels of inhibitors. Virus
was harvested 48 h post transfection as described
[32,33].
Preparation of virus
Virus was harvested from transfected cells, clarified by
low-speed centrifugation and filtration through a 0.22
μm filter as described [32]. We determined the RT
activity using the exogenous template RT assay
described below. To remove RTIs from virus prepara-
tions for subsequent infectivity assays, we added 1/2
volume of ice-cold 30% (wt./vol.) PEG (8000 MW) dis-
solved in 0.5 M NaCl to the infectious supernatant, then
precipitated on ice for at least two h with occasional
mixing. Virus-PEG mixtures were then centrifuged at
low speed (6,800 × g) for 15 min in a prechilled rotor at
4°C. The supernatant was removed by aspiration, and
then the pellets were washed with ice-cold 10% (wt./
vol.) PEG (1/2 volume of 30% [wt./vol.] PEG (8000) pre-
pared with 1 vol. of Dulbecco’sP B Sw i t h o u tC a
2+ or
Mg
2+). After the wash supernatant was removed by
aspiration, the tubes were spun briefly to collect any
remaining supernatant, which was removed by aspira-
tion. The pellets were resuspended in cell culture media
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quent qPCR analysis of virions and endogenous reverse
transcription assays, virus-containing supernatants were
treated with DNase I, pelleted through a 20% sucrose
pad, then treated with subtilisin and pelleted through
another 20% sucrose pad as described [33] (Figure 1,
right).
Infectivity assays
TZM-bl cells in 96-well plates were infected with each
PEG-precipitated virus preparation (Figure 1, left) using
eleven 3-fold serial dilutions, and the final titer was
determined by counting the number of blue colonies in
each well and normalizing to the dilution and virus
input using exogenous-template RT activity as described
[41]. HeLa CD4+ clone 1022 cells were infected with
PEG-precipitated virus for 4 h and cells were harvested
at the indicated time points. DNA from infected cells
was isolated using a Qiagen DNA Blood Mini-Kit, and
viral and cellular DNA sequence targets were quanti-
tated using qPCR as described [32].
Endogenous reverse transcription assays
Virus treated with DNase I and subtilisin (Figure 1,
right) was used in the endogenous reverse transcription
assay as described [33]. In contrast with the endpoint
assays shown previously, we performed a kinetic analysis
by following the progression of reverse transcription
over a time course. To do this, each DNase-subtilisin
treated virus preparation was divided into 7 equal parts.
One part was immediately lysed (50 mM Tris, pH 7.4;
10 mM EDTA; 1% (w/v) SDS; 100 mM NaCl; 50 μg/mL
yeast tRNA; 100 μg proteinase K), extracted twice each
with phenol:chloroform:isoamyl alcohol (25:24:1) and
chloroform, and ethanol precipitated. Viral DNA and
gRNA were quantitated to assess the initial levels of
vDNA and input genomes for the reverse transcription
reactions. The other 6 parts were kept on ice while
endogenous reverse transcription buffer was added to
each tube (final composition after addition to virus sam-
p l e ,5 0m MT r i s - H C l ,p H8 . 0 ,2m MM g C l 2,1 0m M
dithiothreitol, 25 μM [each] dNTPs). All samples were
placed at 37°C simultaneously, and at the indicated
times one part was collected, immediately lysed (as
above) and viral DNA was quantitated to determine pro-
gression of reverse transcription.
Exogenous-template reverse transcriptase assays
Virus containing supernatants (0.75 mL) were clarified
by low speed centrifugation and/or filtration and mixed
with 0.375 mL of 30% (wt./vol.) PEG (8000 MW) dis-
solved in 0.5 M NaCl. Samples were stored overnight at
4°C, precipitates were collected by centrifugation at top
speed in a microfuge, supernatants were removed and
pellets were resuspended in 37.5 μLo f5 0m MT r i s ,
100 mM NaCl, 1 mM EDTA, 2% (vol./vol.) fetal bovine
serum, pH 7.5. The resuspended virus (5 μL) was
assayed in a total volume of 25 μL containing 50 mM
Tris, 100 mM NaCl, 6 mM MgCl2,1 0m Md i t h i o t h r e i -
tol, 4 μg/mL oligo-dT17 (Invitrogen, Carlsbad, CA),
40 μg/mL poly-rA (The Midland Certified Reagent
Company, Inc., Midland, TX), 0.01 μCi [a-
32P]-TTP
(3000 Ci/mmol; Perkin Elmer Life Sciences, Waltham,
MA) and 0.25% (vol./vol.) Nonidet P-40.
Samples were incubated at 37°C for 3 h, then 5 μL
were spotted onto a DEAE Filtermat for the 1450
MicroBeta counter (Perkin Elmer Cat. No.: 1450-5222)
and allowed to dry. Filters were washed 3× in 250 mL
of 0.3 M NaCl, 0.03 M sodium citrate, pH 7.0, for 15
min each, then rinsed twice in 10 mL of 95% (vol./vol.)
ethanol (1 min each) and allowed to dry. The filtermats
were counted using a
32P-Filtermat Cassette (Perkin
Elmer cat. no.: 1450-118) in a Wallac 1450 Microbeta,
6-detector, liquid scintillation counter (Perkin Elmer).
q PCR for vDNA and qRT-PCR for gRNA
Primers and probes were used for quantitation of gRNA
and vDNA using a Stratagene Mx3000P instrument
(Agilent Technologies, Santa Clara, CA). All of the pri-
mers, probes, and PCR conditions used have been
described [32,33]. The targets monitor progression of 4
discrete steps of reverse transcription including minus-
strand strong-stop synthesis (R-U5), minus-strand trans-
fer product (U3-U5), late minus-strand synthesis (Gag),
and plus-strand transfer product (R-5’UTR). For gRNA
determination the primers and probes for gag detection
were used (see bottom of Figure 3 for schematics of the
pertinent vDNA target sites). CCR5 DNA copies were
used to normalize vDNA for cell recovery in infections
(Figure 6) as described [32].
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